FINWIRES · TerminalLIVE
FINWIRES

Biofuel's Weekly Value Changes Seen in Retail Prices for SAF, Renewable Diesel, The Digest Says

-- Weekly retail price for sustainable aviation fuel rose, renewable diesel dropped, and biodiesel remained unchanged, according to price assessments from The Digest.

For the week of Apr. 2-9, biodiesel's Renewable Fuel Standard value of $1.29 per gallon was unchanged from a week ago. Biodiesel's Low Carbon Fuel Standard value of $0.49/gal was unchanged from a week ago. Additionally, the biofuel's tax credit value at $1/gal and energy value of $3.27/gal were unchanged. Biodiesel's retail price of $6.05/gal on Thursday was unchanged from a week ago.

Renewable diesel's retail price of $6.71/gal this week is below $7/gal, down from last week. RD's energy value of $3.93/gal on Thursday was below $4.22/gal from a week ago. RD's RFS value is $1.29/gal, unchanged from a week ago. Its tax credit value at $1/gal was unchanged over the week. RD's LCFS value of $0.49/gal was also unchanged from a week ago.

Ethanol's weekly performance was mixed. Its LCFS value of $0.12/gal, energy value of $0.47/gal, and RFS value of $1.13/gal were unchanged from a week ago. The retail price of $1.72/gal was also unchanged from a week ago.

For sustainable aviation fuel, its energy value at $5.71/gal was above $5.33/gal a week ago. SAF's retail price of $9.03/gal was above $8.65 a week ago. SAF's RFS value was $1.29/gal, unchanged from a week ago. Its LCFS value was $0.49/gal, also unchanged from a week ago, and its tax credit value was unchanged at $1.54/gal.

Note: These values are for delivery into a US market with a clean-fuel standard. Conventional ethanol is modeled at a Carbon Intensity of 70, while RD, SAF, biodiesel, and cellulosic ethanol are modeled at a CI of 20, and green hydrogen at CI -5. Individual companies or processes may have CI scores that are higher or lower than those used to calculate LCFS credits.

相关文章

Asia

企业差旅管理公司预计将冲回至多1.18亿英镑的收入,与之前的业绩相比将出现下滑。

根据周三提交给澳大利亚证券交易所的文件,Corporate Travel Management(ASX:CTD)预计将从2025财年及之前年度的业绩中冲回至多1.18亿英镑的收入,高于此前预估的7760万英镑。 此前,该公司聘请毕马威会计师事务所(KPMG)对部分年度的业绩进行法务会计审查。毕马威在审查中发现,该公司在英国已完成的客户合同和其他收入的确认方面存在一些问题。 该公司表示,根据与部分客户的商业谈判结果,可能需要在上半年业绩中冲回至多约1000万英镑的收入。审查证实,部分客户被收取了高于合同约定的费用。 Corporate Travel Management表示,已对其英国业务进行了“重大调整”,尤其是在财务控制和运营流程方面。该公司还补充说,审查并未在其他地区发现任何问题。 该公司计划在今年第二季度发布经审计的 2025 财年财务报表和经审核的 2026 财年上半年财务报表。

$ASX:CTD
Asia

北方星资源公司3月份季度黄金销售额下降

根据周三提交给澳大利亚证券交易所的文件,北方星资源公司(ASX:NST)表示,截至2025年3月季度,该公司黄金总销量为380,807盎司,综合维持成本(AISC)为每盎司2,709澳元。 此前提交的文件显示,截至2025年3月季度,该公司黄金总销量为385,441盎司,综合维持成本为每盎司2,246澳元。 该公司预计2026财年黄金销量将超过150万盎司,综合维持成本预计在每盎司2,600澳元至2,800澳元之间。 该公司在支付3.47亿澳元现金股息后,净现金为3.2亿澳元,截至3月31日,其现金及贵金属总持有量为11.8亿澳元。 北方之星资源公司(Northern Star Resources)的股价在最近的周三交易中下跌了约2%。

$ASX:NST
Asia

卫材与默克联合开展的肾癌药物三期临床试验未能达到生存终点

日本制药公司卫材(Eisai,TYO:4523)和美国默克公司(Merck)的实验性联合疗法在一项3期临床试验中未能达到无进展生存期和总生存期这两个主要终点。 根据周二发布的联合声明,该试验旨在评估晚期透明细胞肾细胞癌(一种约占所有肾癌病例80%的肾癌)的一线治疗方案。 LITESPARK-012研究在1688名患者中测试了两种方案:Keytruda联合Lenvima和Welireg,以及MK-1308A(Keytruda与一种在研抗体的复方制剂)联合Lenvima,并与已确立的Keytruda联合Lenvima方案进行比较。 中期分析显示,与标准治疗相比,两种实验性联合方案均未能达到该研究的两个主要目标,即改善总生存期和无进展生存期。

$TYO:4523